Cargando…

Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre

BACKGROUND AND OBJECTIVES: HER2 testing guideline of ASCO/CAP for interpretation and reporting has recently been revised. The study is aimed to measure the impact of 2013 CAP guideline on equivocal HER2 test outcome (immunohistochemistry [IHC] 2+) when tested by fluorescent in situ hybridization (FI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panigrahi, Manoj Kumar, Kumar, Dushyant, Mehta, Anurag, Saikia, Kandarpa Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	ORIGINAL ARTICLE: Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506804/ https://www.ncbi.nlm.nih.gov/pubmed/28702401 http://dx.doi.org/10.4103/2278-330X.208841

Ejemplares similares

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction
por: Kumar, Dushyant, et al.
Publicado: (2018)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2019)

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019)

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
por: Nagarjun, B. R., et al.
Publicado: (2022)

The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a retrospective study
por: Thambamroong, Tawasapon
Publicado: (2022)

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals
por: Mehta, Anurag, et al.
Publicado: (2021)

Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India
por: Mehta, Anurag, et al.
Publicado: (2018)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
por: van der Velden, Bas H. M., et al.
Publicado: (2018)

2007 EORTC-NCI-ASCO Annual Meeting: Molecular Markers in Cancer
por: Lukan, C
Publicado: (2008)

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
por: Kim, Gilhyang, et al.
Publicado: (2016)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Diagnostic ability of real-time quantitative polymerase chain reaction versus immunohistochemistry for Ki-67 assessment in breast cancer: An Indian perspective
por: Mehta, Anurag, et al.
Publicado: (2019)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer: a systematic review
por: Robertson, Clare, et al.
Publicado: (2011)

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
por: Kwak, Yoonjin, et al.
Publicado: (2017)

Invasive Colloid Carcinoma and the role of Ki-67 and HER2 – Two case reports
por: Patel, Sarvanand, et al.
Publicado: (2018)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

Autologous Breast Reconstruction after Mastectomy for Breast Cancer: A Systematic Review
por: Saldanha, Ian J., et al.
Publicado: (2022)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Implant-based Breast Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis
por: Saldanha, Ian J., et al.
Publicado: (2022)

Implant-based versus Autologous Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis
por: Broyles, Justin M., et al.
Publicado: (2022)

Primary extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor of breast
por: Srivastava, Smita, et al.
Publicado: (2016)

Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
por: Ducreux, Michel
Publicado: (2009)

Characterization of lesions in dense breasts: Does tomosynthesis help?
por: Rangarajan, Krithika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q32pdilnpccipm0bbpp24pcb6u